CO6680674A2 - Matrix metalproteinase inhibitors - Google Patents

Matrix metalproteinase inhibitors

Info

Publication number
CO6680674A2
CO6680674A2 CO13040146A CO13040146A CO6680674A2 CO 6680674 A2 CO6680674 A2 CO 6680674A2 CO 13040146 A CO13040146 A CO 13040146A CO 13040146 A CO13040146 A CO 13040146A CO 6680674 A2 CO6680674 A2 CO 6680674A2
Authority
CO
Colombia
Prior art keywords
compounds
over
relates
present
matrix
Prior art date
Application number
CO13040146A
Other languages
Spanish (es)
Inventor
Manjo Kumar Khera
Jitendra Sattigeri
Viswajanani Sattigeri
Neeraj Kumar Yadav
Kewal Kumar
Adbul Rehman Rauf
Ian Anthony Cliffe
Pradip Bhatnagar
Abhijit Ray
Punit Kumar Srivastava
Sunanda Ghosh Dastidar
Original Assignee
Ranbaxy Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Lab Ltd filed Critical Ranbaxy Lab Ltd
Publication of CO6680674A2 publication Critical patent/CO6680674A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/08—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

La presente invención se relaciona con ciertos derivados de ácido hidroxipropiónico y los procesos para la síntesis de los mismos. La invención también se relaciona con composiciones farmacológicas que contienen los compuestos de a presente invención, y métodos para el tratamiento de asma, artritis reumatoidea, COPD, rinitis, osteoartritis, artritis psoriásica, psoriasis, fibrosis pulmonar, inflamación pulmonar, síndrome de dificultad respiratoria aguda, periodontitis, esclerosis múltiple, gingivitis, ateroesclerosis, ojo seco, proliferación neointimal, que conduce a la restenosis y a la insuficiencia cardíaca isquémica, ataque apopléjico, enfermedades renales, metástasis tumoral, y otros desórdenes inflamatorios caracterizados por la sobre-expresión y la sobre-activación de una metaloproteinasa de matriz utilizando los compuestos.The present invention relates to certain hydroxypropionic acid derivatives and the processes for their synthesis. The invention also relates to pharmacological compositions containing the compounds of the present invention, and methods for the treatment of asthma, rheumatoid arthritis, COPD, rhinitis, osteoarthritis, psoriatic arthritis, psoriasis, pulmonary fibrosis, pulmonary inflammation, acute respiratory distress syndrome , periodontitis, multiple sclerosis, gingivitis, atherosclerosis, dry eye, neointimal proliferation, which leads to restenosis and ischemic heart failure, apoplectic attack, kidney diseases, tumor metastasis, and other inflammatory disorders characterized by over-expression and over- activation of a matrix metalloproteinase using the compounds.

CO13040146A 2010-07-30 2013-02-28 Matrix metalproteinase inhibitors CO6680674A2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN1810DE2010 2010-07-30

Publications (1)

Publication Number Publication Date
CO6680674A2 true CO6680674A2 (en) 2013-05-31

Family

ID=44720049

Family Applications (1)

Application Number Title Priority Date Filing Date
CO13040146A CO6680674A2 (en) 2010-07-30 2013-02-28 Matrix metalproteinase inhibitors

Country Status (11)

Country Link
EP (1) EP2598493A1 (en)
JP (1) JP2013537533A (en)
KR (1) KR20130042590A (en)
CN (1) CN103119030A (en)
AU (1) AU2011284397A1 (en)
BR (1) BR112013002370A2 (en)
CA (1) CA2807097A1 (en)
CO (1) CO6680674A2 (en)
MX (1) MX2013001240A (en)
SG (1) SG187654A1 (en)
WO (1) WO2012014114A1 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6360040B2 (en) 2012-05-03 2018-07-18 カラ ファーマシューティカルズ インコーポレイテッド Mucus-permeable coated particles, compositions, pharmaceutical compositions, pharmaceutical formulations, and methods for forming them
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
EP4008355A1 (en) 2012-05-03 2022-06-08 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
WO2014127214A1 (en) 2013-02-15 2014-08-21 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
AU2014219024B2 (en) 2013-02-20 2018-04-05 KALA BIO, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
CN103304634B (en) * 2013-05-30 2015-04-29 温州芳植生物科技有限公司 Matrix metalloproteinase-2 polypeptide inhibitor and application
CN103254290B (en) * 2013-05-30 2014-09-03 南通广泰生化制品有限公司 Matrix metal proteinase-2 polypeptide inhibitors and application thereof
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
AU2014342042B2 (en) 2013-11-01 2017-08-17 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof
WO2015150366A1 (en) * 2014-04-03 2015-10-08 Bayer Pharma Aktiengesellschaft Cyclically substituted phenol ether derivatives and use thereof
WO2015150350A1 (en) 2014-04-03 2015-10-08 Bayer Pharma Aktiengesellschaft 2,5-disubstituted cyclopentane carboxylic acids for the treatment of respiratoy tract diseases
WO2015150363A1 (en) 2014-04-03 2015-10-08 Bayer Pharma Aktiengesellschaft 2,5-disubstituted cyclopentane carboxylic acids and use thereof
WO2015150364A1 (en) * 2014-04-03 2015-10-08 Bayer Pharma Aktiengesellschaft Substituted benzotriazinone butane acids and use thereof
US20170119776A1 (en) 2014-04-03 2017-05-04 Bayer Pharma Aktiengesellschaft Chiral 2,5-disubstituted cyclopentanecarboxylic acid derivatives and use thereof
WO2015189117A1 (en) * 2014-06-12 2015-12-17 Bayer Pharma Aktiengesellschaft Heterobicyclically substituted 4-oxobutane acid derivatives and use thereof
JOP20190024A1 (en) 2016-08-26 2019-02-19 Gilead Sciences Inc Substituted pyrrolizine compounds and uses thereof
US10392399B2 (en) 2016-09-08 2019-08-27 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CA3036336A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
BR112019004463A2 (en) 2016-09-08 2019-05-28 Kala Pharmaceuticals Inc crystalline forms of therapeutic compounds, their processes for obtaining and their methods of use
EP3759109B1 (en) 2018-02-26 2023-08-30 Gilead Sciences, Inc. Substituted pyrrolizine compounds as hbv replication inhibitors

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1200886A (en) 1966-09-23 1970-08-05 Allen & Hanburys Ltd Phenylaminoethanol derivatives
US3937838A (en) 1966-10-19 1976-02-10 Aktiebolaget Draco Orally active bronchospasmolytic compounds and their preparation
US3700681A (en) 1971-02-16 1972-10-24 Pfizer 2-hydroxymethyl-3-hydroxy-6-(1-hydroxy-2-aminoethyl)pyridines
US3994974A (en) 1972-02-05 1976-11-30 Yamanouchi Pharmaceutical Co., Ltd. α-Aminomethylbenzyl alcohol derivatives
US4011258A (en) 1973-06-21 1977-03-08 Aktiebolaget Draco Orally active bronchospasmolytic compounds
CY1273A (en) 1980-07-09 1985-03-08 Draco Ab 1-(dihydroxyphenyl)-2-amino-ethanol derivatives;preparation,compositions and intermediates
ZW6584A1 (en) 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
CA1240708A (en) 1983-11-15 1988-08-16 Johannes K. Minderhoud Process for the preparation of hydrocarbons
GB9304919D0 (en) 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
IL151250A0 (en) 2000-03-21 2003-04-10 Procter & Gamble Difluorobutyric acid metalloprotease inhibitors
CA2433516A1 (en) 2001-01-30 2002-08-08 Keith Michael Devries Processes for preparing chromanylbenzoic acids
US6794510B2 (en) 2002-08-08 2004-09-21 Adolor Corporation Processes for the preparation of peripheral opioid antagonist compounds and intermediates thereto
GB0312654D0 (en) 2003-06-03 2003-07-09 Glaxo Group Ltd Therapeutically useful compounds
GB0314488D0 (en) 2003-06-20 2003-07-23 Glaxo Group Ltd Therapeutically useful compounds
GB0321538D0 (en) 2003-09-13 2003-10-15 Glaxo Group Ltd Therapeutically useful compounds
ES2381681T3 (en) 2005-02-22 2012-05-30 Ranbaxy Laboratories Limited 5-Phenyl-pentanoic acid derivatives as inhibitors of matrix metalloproteinase for the treatment of asthma and other diseases
CN101528691B (en) 2006-08-22 2014-11-26 兰贝克赛实验室有限公司 Matrix metalloproteinase inhibitors

Also Published As

Publication number Publication date
WO2012014114A1 (en) 2012-02-02
BR112013002370A2 (en) 2017-06-20
KR20130042590A (en) 2013-04-26
JP2013537533A (en) 2013-10-03
AU2011284397A1 (en) 2013-02-21
SG187654A1 (en) 2013-03-28
CA2807097A1 (en) 2012-02-02
CN103119030A (en) 2013-05-22
MX2013001240A (en) 2013-08-27
EP2598493A1 (en) 2013-06-05

Similar Documents

Publication Publication Date Title
CO6680674A2 (en) Matrix metalproteinase inhibitors
EA201390404A1 (en) INHIBITORS OF MATRIC METAL PROTEINASE
BR112013006929A2 (en) compound of formula I, pharmaceutical composition, process for preparing compounds of formula 9, 16, 20, 27 and 30
CU20110134A7 (en) INHIBITORS OF THE METALOPROTEINASE MATRIX
CY1118475T1 (en) ANTI-OXYGEN INFLAMMATORY REGULATORS: C-17 OLANOLIC ACID PRODUCERS
CY1120660T1 (en) NEW TOY RIG-I SUBSTITUTES AND METHODS OF THEIR PRODUCTION
BR122019015876B8 (en) compounds derived from 1,2,5-oxadiazoles, composition, as well as their uses
CO7131358A2 (en) N-alkyltriazole compounds as lpar antagonists
PE20210922A1 (en) PYRIMIDINONES AS INHIBITORS OF THE XIA FACTOR
BR112012017448A2 (en) method for the preparation of tetrazole methanesulfonic acid salts and a new compound employed therein
BR112013028667A2 (en) process for producing a carboxylic acid composition
PE20150185A1 (en) DIMETHYL BENZOIC ACID COMPOUNDS
CO6341581A2 (en) HETEROARILO DERIVATIVES AS DGAT1 INHIBITORS
CL2018001541A1 (en) Diastereoselective synthesis of phosphate derivatives and gemcitabine prodrug nuc-1031.
UY32467A (en) AMINAS ADDITION SALTS CONTAINING HYDROXYL AND / OR CARBOXILIC GROUPS WITH AMINONICOTINIC ACID DERIVATIVES AS DHODH INHIBITORS
CO7160077A2 (en) Pyrazole compounds substituted as lpar antagonists
NI200700220A (en) DERIVATIVES OF 5-PHENYL-PENTANOIC ACID AS INHIBITORS OF METALOPROTEINASE IN THE MATRIX FOR THE TREATMENT OF ASTHMA AND OTHER DISEASES
CL2011000296A1 (en) Process for preparing 4-oxo-octahydro-indole-1-carboxylic acid methyl ester and intermediate compounds used.
UA111868C2 (en) METHOD OF PREPARING ETHERS (5-FLUOR-2-METHYL-3-QUINOLIN-2-ILMETHYLINDOL-1-IL) -ACETIC ACID
BR112012013582A2 (en) process for synthesis of intermediates useful for the production of substituted indazole and azaindazole compounds
CL2011000093A1 (en) Compounds derived from a piperidinyl ester of biphenyl-2-ylcarbamic acid; pharmaceutical composition; pharmaceutical combination; and its use for bronchoconstriction, obstructive or inflammatory diseases of the respiratory tract.
CR20120630A (en) NEW PROCESS
BR112015023343A2 (en) method of preparing sovaprevir, method of preparing a compound of formula (c), method of preparing compound f-2, compound, process, method of preparing a pure amorphous form of sovaprevir, and crystalline form of sovaprevir
CU23718B7 (en) DERIVATIVES OF 5-PHENYL-PENTANOIC ACID AS INHIBITORS OF THE METALOPROTEINASE OF THE MATRIX.
UY33507A (en) PROCESS FOR THE PREPARATION OF ENOLATE SALTS OF 4-FLUORO-2-HYDROXIMETHYLENE-3-OXO-BUTIRATES

Legal Events

Date Code Title Description
FA Application withdrawn